WP 5: EU-OPENSCREEN Strategy
July 2012 - Month 18 Update
WP5 reached a very important milestone, the interim agreement of the consortium on EU-OPENSCREEN’s future services, scope and strategy, which affects the Preparatory Phase project as a whole.
- Development of a refined user concept.
- Refinement of the EU-OPENSCREEN strategy.
- Development of a construction plan for the EU-OPENSCREN infrastructure.
- Agreement on a Code of Conduct for the operation of the future EU-OPENSCREEN infrastructure.
- Agreement on a business plan for the construction and operational phase.
|D5.1 Report on survey of existing infrastructures||April 2011||Public [click here]|
|D5.2 Report on user survey||April 2011||Public [click here]|
|D5.3 Report on refined user service concept and portfolio||October 2011||Public [click here]|
|D5.4 Impact study||January 2012||Public [click here]|
|D5.5 Report on the refined EU-OPENSCREEN strategy||April 2012||Public [click here]|
|D5.6 Proposal of a draft frame for the EU-OPENSCREEN infrastructure||October 2012||Restricted|
|D5.7 Code of Conduct document||October 2012||Public [click here]|
|D5.8 Proposal for a layout of the EU-OPENSCREEN infrastructure||February 2013||Restricted|
|D5.9 Construction plan||April 2013||Restricted|
|D5.10 Business plan||October 2013||Restricted|
The EU-OPENSCREEN Industrial Advisory Group
|Philip Gribbon (Chair)||European ScreeningPort||Philip.Gribbon@screeningPort.com|
|Jeremy Everett||University of Greenwich||J.R.Everett@greenwich.ac.uk|
|Thierry Langer||Prestwick Chemical||Thierry.firstname.lastname@example.org|
|Ulrich Stilz||Sanofi Aventis||Ulrich.Stilz@sanofi-aventis.com|
EU-OPENSCREEN Strategy Group
The EU-OPENSCREEN Strategy Group is chaired by Dr James Inglese, Deputy Director of the NIH Chemical Genomics Centre at the National Human Genome Research Institute, National Institutes of Health (USA).